CXCL10 and COVID-19: Importantly, our meta-analysis identified 4 potential novel targets (CCL20, CSF3, CXCL1, CXCL10) associated with COVID-19 pathogenesis, targeted by 6 existing drugs that have not been studied in clinical trials for treatment of COVID-19 and could be repurposed.